DEY ^® Brand Generics
safety advancements:

• Secure foil overwrapping
  helps lock out airborne viruses
  and contaminants
• Bar coding on secure foil
  packaging and carton helps
  eliminate dispensing errors
  and associated costs
• Color coding on packaging
  helps avoid mix-ups with other medicines
• Embossed vials for quick identification and safe dispensing procedures

Ipratropium Bromide Inhalation Solution is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with COPD. Please see full prescribing information.

The most common adverse events (≥3%) reported include lower respiratory disorders (bronchitis, dyspnea, and bronchospasm). Headache, mouth dryness, and aggravation of COPD symptoms are more common when the total daily dose of Ipratropium Bromide equals or exceeds 2,000 mcg. Allergic-type reactions, such as skin rash; angioedema of tongue, lips, and face; urticaria; laryngospasm; and anaphylactic reaction, have been reported.

DEY^® is a registered trademark of Dey, L.P.
Atrovent^® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc.